Novartis Targets 5% Annual Sales Growth Through 2031 Despite Patent Expirations
The Swiss drugmaker lifted peak sales targets for three medicines to $18 billion combined as it seeks to offset looming patent losses and recent trial setbacks.
- On Thursday, Drugmaker Novartis set a 5% annual sales growth target through 2031, aiming to offset patent expiries and recover from recent late-stage clinical study setbacks.
- The company raised its peak sales forecast for Kesimpta, Scemblix, and Leqvio to $18 billion combined, up from $14 billion, to counter competition facing older blockbusters.
- Peak sales for Kisqali are forecast at $10 billion, with increased expectations of $8 billion for Kesimpta and $5 billion each for Scemblix and Leqvio.
- Following a $2.2 billion writedown this year, shares fell 2.4% in Switzerland as investors scrutinized CEO Vas Narasimhan's dealmaking strategy.
- CEO Vas Narasimhan expects growth beyond 2031 to come from internal medicines, with M&A contributions remaining consistent with the $63 billion spent on business development over the last decade.
17 Articles
17 Articles
Novartis Targets 5% Annual Sales Growth Through 2031 Despite Patent Expirations
Novartis (NYSE:NVS) expects annual sales growth of 5% from 2026 through 2031 and average mid-single-digit growth into the mid-2030s, as the drugmaker looks to offset patent expirations with newer medicines and its development pipeline. CEO Vas Narasimhan outlined the forecast at the company’s Meet
Novartis predicted a steady growth in sales until 2031, highlighting the momentum generated by medicines already present in the market and by future launches; the company also stated that the drugs in its development portfolio will help sustain long-term growth. Exclusive material for subscribers. To have full access, access the link of the material and register.
Novartis Trims Sales-Growth Outlook Before Investor Meeting
Novartis targets 5% annual sales growth through 2031
Novartis bets on bigger blockbusters to power growth, forecasting 5% annual sales through 2031
The drugmaker cited strong demand for its blockbuster drugs as it upgraded peak sales forecasts for multiple sclerosis, leukemia, and cholesterol medicines.
Coverage Details
Bias Distribution
- 63% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium


















